Karyopharm Therapeutics

Targeting Disease
at the Nuclear Pore

Discover Now

23rd European Hematology Association
(EHA) Congress

14-17
June
2018

European Hematology Association

Stockholm, Sweden
June 14 - 17, 2018

READ MORE

23rd European Hematology Association (EHA) Congress

14-17
June
2018

European Hematology Association

Stockholm, Sweden
June 14 - 17, 2018

READ MORE

23rd European Hematology Association (EHA) Congress

14-17
June
2018

European Hematology Association

Stockholm, Sweden
June 14 - 17, 2018

READ MORE

About Karyopharm

Karyopharm Therapeutics Inc. is a clinical-stage pharmaceutical company focused on discovery and development of novel first-in-class drugs directed against nuclear transport and related targets for the treatment of cancer and other major diseases.

Learn More

Pipeline

Our Drug Candidates:
SINE™ Compounds and PAK4 Inhibitors

View Pipeline

Stock Quote (KPTI)

Investor Information

Service temporary unavailable

18.680

-0.150  (-0.8%)

2018-06-22 16:00:00

Previous Close 18.830
Open 18.970
Volume 3,099,119
Exchange NASDAQ
Day High 19.250
Day Low 18.150
52-Week High 20.390
52-Week Low 8.000

Publications

Scientific Papers, Posters and Presentations on Karyopharm pipeline compounds

Visit Archive

Papers

Posters & Presentations

Patients & Caregivers

Learn More

USA
Karyopharm Therapeutics

  • Corporate Headquarters:
  • 85 Wells Ave., 2nd floor
  • Newton, MA 02459
  •  
  • Main Phone Number (USA)
  • 617-658-0600

GERMANY
Karyopharm Therapeutics

  • Sitz der Gesellschaft:
  • Karyopharm Europe GmbH
  • Franziska-Bilek-Weg 9
  • 80339 München
  • Germany
  •  
  • Tel.: +49 (0) 89 – 54 84 86-101
  • Fax: +49 (0) 89 – 54 84 86-200

© 2018 Karyopharm Therapeutics

Terms of Use Privacy Policy